Background

Emeritus Professor Gregory Tannock’s current research interests include the causes of variability in the growth of influenza B viruses in eggs, development of methods for increasing yields of vaccine antigens; Development and evaluation of live attenuated vaccines against influenza (publication record over 30 years); Evaluation of broad-spectrum antiviral drugs against respiratory viruses, especially influenza and RSV; Development of improved methodologies for the rapid diagnosis of viral infections; Studies with avian viruses and, in particular, Marek’s disease virus. Emeritus Professor Tannock is a Member, Editorial Board: Journal of Medical Virology (2001-) and Biomedical Research International (2007-). Independent “voting member” (one of four) of the Australian Influenza Vaccine Committee of the Therapeutic Goods Administration, Commonwealth Department of Health. Principal Supervisor for 13 PhD, five M.App.Sc/M.MedSci, 13 Honours candidates (all completed).

Positions

• 2015: Visiting Professor, Brawijaya University, Indonesia, Faculty of Medicine.
• 2006: Visiting Professor and Guest Lecturer, University of Natural Resources and Applied Life Sciences, Vienna, Austria,
• 2008-present: Burnet Institute Visiting Fellow, Burnet Institute, Victoria, Australia
• 1993-2007: Professor of Virology, Royal Melbourne Institute Technology, Victoria, Australia
• 1990: Visiting Fellow, Department of Microbiology, The University of Melbourne, Victoria, Australia
• 1986-1987: Visiting Scientist, Respiratory and Enterovirus Branch, CID CDC Atlanta GA, USA
• 1979-1993: Senior Lecturer and Associate Professor of Pathology (Microbiology), Faculty of Medicine, The University of Newcastle, NSW, Australia.
• 1977-1979: Virologist, CSL Ltd.
• 1975-1976: Visiting Fellow, Virology Division, CDC, Atlanta GA, USA
• 1973-1975: Virologist, CSL Ltd.
• 1970-1973: Tutor in Biochemistry, Newman College, University of Melbourne
• 1966-1969: Research Scholar, John Curtin School of Medical Research, Australian National University, Australia
• 1969-1973: Virologist, National Biological Standards Laboratory,Victoria, Australia
• 1960-1961: Virologist, CSL Ltd

Qualifications

• 1996: DSc, Newcastle University, New South Wales, Australia
• 1970: PhD, Australian National University, Australian Capital Territory, Australia
• 1966: MSc, University of Western Australia, Australia
• 1960: BSc, University of Western Australia, Australia

Awards

• 2009: Royal Society Visiting Fellowship, Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom
• 2002-2003: Wellcome Fellowship, National Institute for Medical Research, Mill Hill, London, United Kingdom
• 2002: Fellow, Australian Society for Microbiology, Australia
• 1999-2000: Wellcome Fellowship, The Queen’s University of Belfast, Northern Ireland, United Kingdom
• 1999: Awarded D.I. Ivanovsky Medal for distinguished services to Virology by the Russian Academy of Medical Sciences, Russia
• 1975-1976: US Public Health Service Post-Doctoral Fellowship, CDC, Atlanta GA, USA
• 1966-1969: Commonwealth Public Service Postgraduate Scholarship, John Curtin School of Medical Research, ANU
• 1958-1959 Commonwealth Scholarship, UWA

Publications (88)

2015 (1)

• Cold adaptation generates mutations associated with the growth of influenza B vaccine viruses.
  Kim H, Velkov T, Camuglia S, Rockman SP, Tannock GA
  Vaccine. 2015 Sep; 33(43):5786-5793

2014 (1)

• Cold adaptation improves the growth of seasonal influenza B vaccine viruses.
  Kim H, Schoofs P, Anderson DA, Tannock GA, Rockman SP
  Vaccine. 2014 Mar; 32(21):2474-2479

2012 (3)

• Pathotyping of Australian isolates of Marek's disease virus and association of pathogenicity with meq gene polymorphism.
  Renz KG, Cooke J, Clarke N, Cheetham BF, Hussain Z, Fakhrul Islam AF, Tannock GA, Walkden-Brown SW
  Avian Pathol. 2012 Apr; 41(2):161-76
• Gordon Alexander Firth 1945-2011
  Tannock G, Henderson A, Mackenzie C, Glastonbury J
  Aust Vet J. 2012 Jan; 19:156
• Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions.
  Brooks MJ, Burtseva EI, Ellery PJ, Marsh GA, Lew AM, Slepushkin AN, Crowe SM, Tannock GA
  J Med Virol. 2012 Jan; 84(1):170-181

2009 (1)

• The detection of influenza A and B viruses in clinical specimens using a quartz crystal microbalance.
  Peduru Hewa TM, Tannock GA, Mainwaring DE, Harrison S, Fecondo JV
  J Virol Methods. 2009 Dec; 162(1-2):14-21

2008 (2)

• Optimization of methods for the isolation of Marek's disease viruses in primary chicken cell cultures.
  Jianming Tan, Julie Cooke, Nadeene Clarke, Gregory A Tannock
  J Virol Methods. 2008 Feb; 147(2):312-318
• Cell-based influenza vaccines: progress to date.
  Audsley JM, Tannock GA
  Drugs. 2008 Jan; 68(11):1483-1491

2007 (1)

• Molecular evaluation of responses to vaccination and challenge by Marek's disease viruses.
  Jianming Tan, Julie Cooke, Nadeene Clarke, Gregory A Tannock
  Avian Pathol. 2007 Oct; 36(5):351-359

2005 (4)

• Pulmonary CD4+ cytokine responses in mice reveal differences in the relative immunogenicity of cold-adapted influenza A vaccine donor strains.
  Mark D Wareing, Leonard C Harrison, Gregory A Tannock
  Vaccine. 2005 Jul; 23(31):4075-4081
• Role of viral load in the pathogenesis of chicken anemia virus.
  Jianming Tan, Gregory A Tannock
  J Gen Virol. 2005 May; 86(Pt 5):1327-1333
• The role of reverse genetics in the development of vaccines against respiratory viruses.
  G A Marsh, G A Tannock
  Expert Opin Biol Ther. 2005 Mar; 5(3):369-380
• The growth of attenuated influenza vaccine donor strains in continuous cell lines.
  J M Audsley, G A Tannock
  J Virol Methods. 2005 Feb; 123(2):187-193

2004 (3)

• The changing face of virology: will the application of molecular techniques inevitably lead to new and better vaccines?
  Gregory A Tannock
  Expert Rev Anti Infect Ther. 2004 Oct; 2(5):663-666
• Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline?
  Megan J Brooks, Joseph J Sasadeusz, Gregory A Tannock
  Curr Opin Pulm Med. 2004 May; 10(3):197-203
• The role of cell culture vaccines in the control of the next influenza pandemic.
  J M Audsley, G A Tannock
  Expert Opin Biol Ther. 2004 May; 4(5):709-717

2003 (4)

• Route of administration is the prime determinant of IgA and IgG2a responses in the respiratory tract of mice to the cold-adapted live attenuated influenza A donor strain A/Leningrad/134/17/57.
  M D Wareing, G A Tannock
  Vaccine. 2003 Jul; 21(23):3097-3100
• A modified blocking ELISA for the detection of antibody to chicken anaemia virus using an Australian strain.
  G A Tannock, J Tan, K A Mawhinney, D Todd, D O'Rourke, T J Bagust
  Aust Vet J. 2003 Jul; 81(7):428-430
• Field evaluations of safety and efficacy of an Australian Marek's disease vaccine.
  R C Karpathy, G A Firth, G A Tannock
  Aust Vet J. 2003 Apr; 81(4):222-225
• An evaluation of the genetic stability and pathogenicity of the Russian cold-adapted influenza A donor strains A/Leningrad/134/17/57 and A/Leningrad/134/47/57 in ferrets.
  G A Marsh, J M Watson, W E White, G A Tannock
  J Virol Methods. 2003 Jan; 107(1):63-69

2002 (3)

• Preparation and characterisation of attenuated cold-adapted influenza A reassortants derived from the A/Leningrad/134/17/57 donor strain.
  M D Wareing, G A Marsh, G A Tannock
  Vaccine. 2002 May; 20(16):2082-2090
• Influenza update: vaccine development and clinical trials.
  Mark D Wareing, Gregory A Tannock
  Curr Opin Pulm Med. 2002 May; 8(3):209-213
• Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus.
  R C Karpathy, G A Firth, G A Tannock
  Aust Vet J. 2002 Jan; 80(1-2):61-66

2001 (4)

• The antigenicity of the chicken anaemia virus protein VP3 (Apoptin).
  S C Cunningham, A M Lew, G A Tannock
  Avian Pathol. 2001 Dec; 30(6):613-619
• Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice.
  M D Wareing, J M Watson, M J Brooks, G A Tannock
  J Med Virol. 2001 Sep; 65(1):171-177
• Live attenuated vaccines against influenza; an historical review.
  Wareing MD, Tannock GA.
  Vaccine. 2001 May; 19((25-26)):3320-30.
• Adaptation of Marek's disease virus to the Vero continuous cell line.
  D Jaikumar, K M Read, G A Tannock
  Vet Microbiol. 2001 Mar; 79(1):75-82

1998 (1)

• The development and evaluation of two tissue culture-grown Marek's disease challenge viruses.
  D B De Laney, C J Morrow, K M Read, G A Tannock
  Avian Pathol. 1998 Jan; 27(5):472-477

1997 (2)

• Protective responses in mice to vaccination with multiply administered cold-adapted influenza vaccine reassortants and wild-type viruses.
  J R Romanova, G A Tannock, G I Alexandrova
  Vaccine. 1997 Apr; 15(6-7):653-658
• Options for the control of influenza III. Cairns, North Queensland, Australia (4-9 May 1996).
  G L Ada, G A Tannock, A W Hampson
  Vaccine. 1997 Feb; 15(3):245-247

1995 (2)

• Isolation of serotype 1 Marek's disease viruses from vaccinated Australian flocks.
  D B De Laney, A E Jones, M Zerbes, G A Tannock
  Vet Microbiol. 1995 Sep; 46(1-3):213-219
• The immunogenicity of reassortants of the cold-adapted influenza A master strain A/Ann Arbor/6/60 is determined by both the genes for cold-adaptation and the haemagglutinin gene.
  G A Tannock, J R Romanova, J A Paul
  Arch Virol. 1995 Jan; 140(1):201-209

1994 (3)

• Avian encephalomyelitis: a review.
  G A Tannock, D R Shafren
  Avian Pathol. 1994 Dec; 23(4):603-620
• Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice.
  J R Romanova, T A Ermachenko, G I Alexandrova, G A Tannock
  Vaccine. 1994 Jan; 12(1):23-27
• Some characteristics of a recent virulent isolate of Marek's disease virus.
  M Zerbes, G A Tannock, R J Jenner, P L Young
  Aust Vet J. 1994 Jan; 71(1):21-22

1993 (3)

• A study of respiratory infections in a healthy adult population during the 1987 Australian winter.
  G A Tannock, A L Reid, S M Gillett, R Herd, R S Gillett, M J Hensley, R D Barry, I P Lawrance, J Nichols, M Adams
  Fam Pract. 1993 Dec; 10(4):378-386
• A study of the advantages and limitations of immunoblotting procedures for the detection of antibodies against influenza virus.
  G P Kapaklis-Deliyannis, H E Drummer, L E Brown, G A Tannock, D C Jackson
  Electrophoresis. 1993 Sep; 14(9):926-936
• Subgrouping of respiratory syncytial virus strains from Australia and Papua New Guinea by biological and antigenic characteristics.
  J C Hierholzer, G A Tannock, C M Hierholzer, R A Coombs, M L Kennett, P A Phillips, I D Gust
  Arch Virol. 1993 Jan; 136(1-2):133-147

1992 (4)

• Laboratory diagnosis of Mycoplasma pneumoniae infection. 4. Antigen capture and PCR-gene amplification for detection of the Mycoplasma: problems of clinical correlation.
  J Williamson, B P Marmion, D A Worswick, T W Kok, G Tannock, R Herd, R J Harris
  Epidemiol Infect. 1992 Dec; 109(3):519-537
• Antibody responses to avian encephalomyelitis virus vaccines when administered by different routes.
  D R Shafren, G A Tannock, P J Groves
  Aust Vet J. 1992 Nov; 69(11):272-275
• Further evidence that the nucleic acid of avian encephalomyelitis virus consists of RNA.
  D R Shafren, G A Tannock
  Avian Dis. 1992 Oct; 36(4):1031-1033
• Western blot analysis of antibody responses to influenza virion proteins.
  D Qiu, G A Tannock, R D Barry, D C Jackson
  Immunol Cell Biol. 1992 Jun; 70 ( Pt 3):181-191

1991 (4)

• Pathogenesis of avian encephalomyelitis viruses.
  D R Shafren, G A Tannock
  J Gen Virol. 1991 Nov; 72 ( Pt 11):2713-2719
• Efficacy of Australian vaccines against recent isolates of avian infectious bronchitis viruses.
  Y Arvidson, G A Tannock, M Zerbes, J Ignjatovic
  Aust Vet J. 1991 Jun; 68(6):211-212
• Alternatives in the control of influenza.
  G A Tannock
  Med J Aust. 1991 May; 154(10):692-695
• Measurement of IgM responses to a subunit influenza A vaccine by sucrose-gradient centrifugation and membrane-filtration enzyme immunoassays.
  G A Tannock, D A Bryce, G R Barnett, A W Hampson, M J Hensley, N A Saunders
  Biologicals. 1991 Jan; 19(1):17-21

1990 (2)

• Development and application of an improved infectivity assay for the standardization of avian encephalomyelitis vaccines.
  D R Shafren, G A Tannock
  Vaccine. 1990 Jun; 8(3):283-285
• A model for determining immunogenic relationships between avian infectious bronchitis viruses.
  Y Arvidson, G A Tannock, A Senthilselvan, M Zerbes
  Arch Virol. 1990 Jan; 111(3-4):227-238

1989 (3)

• Diagnosis of a field outbreak of avian encephalomyelitis by enzyme-linked immunosorbent assay.
  D R Shafren, G A Tannock, C J Morrow
  Aust Vet J. 1989 Jul; 66(7):224-225
• Improved colorimetric assay for detecting influenza B virus neutralizing antibody responses to vaccination and infection.
  G A Tannock, J A Paul, R Herd, R D Barry, A L Reid, M J Hensley, R S Gillett, S M Gillett, P Lawrance, R L Henry
  J Clin Microbiol. 1989 Mar; 27(3):524-528
• Development and application of an ELISA technique for the detection of antibody to avian encephalomyelitis viruses.
  D R Shafren, G A Tannock, T K Roberts
  Res Vet Sci. 1989 Jan; 46(1):95-99

1988 (3)

• A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers.
  G A Tannock, S M Gillett, R S Gillett, R D Barry, M J Hensley, R Herd, A L Reid, N A Saunders
  Epidemiol Infect. 1988 Dec; 101(3):611-621
• An improved membrane-filtration enzyme immunoassay for the rapid serological diagnosis of viral infections.
  G R Barnett, G A Tannock, J A Paul, D A Bryce
  J Virol Methods. 1988 Aug; 20(4):323-332
• An enzyme-linked immunosorbent assay for the detection of avian encephalomyelitis virus antigens.
  D R Shafren, G A Tannock
  Avian Dis. 1988 Apr; 32(2):209-214

1987 (3)

• Freeze-drying of respiratory syncytial viruses for transportation and storage.
  G A Tannock, J C Hierholzer, D A Bryce, C F Chee, J A Paul
  J Clin Microbiol. 1987 Sep; 25(9):1769-1771
• Membrane filtration enzyme immunoassay, a novel, rapid method for measurement of virus-specific immunoglobulins G and M and detection of viral antigens.
  G R Barnett, G A Tannock, D A Bryce
  J Clin Microbiol. 1987 Feb; 25(2):385-390
• Homotypic and heterotypic immunity of influenza A viruses induced by recombinants of the cold-adapted master strain A/Ann Arbor/6/60-ca.
  G A Tannock, J A Paul
  Arch Virol. 1987 Jan; 92(1-2):121-133

1986 (1)

• Respiratory syncytial virus: a review of the virus, its epidemiology, immune response and laboratory diagnosis.
  J C Hierholzer, G A Tannock
  Aust Paediatr J. 1986 May; 22(2):77-82

1985 (4)

• Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/60-ca.
  G A Tannock, D A Bryce, J A Paul
  Vaccine. 1985 Sep; 3(3):333-339
• Immunization against influenza by the ocular route.
  G A Tannock, J A Paul, R D Barry
  Vaccine. 1985 Sep; 3(3 Suppl):277-280
• A rapid procedure for the purification of avian encephalomyelitis viruses.
  G A Tannock, D R Shafren
  Avian Dis. 1985 Apr; 29(2):312-321
• A device for the nondestructive decontamination of large volumes of infected egg waste.
  N R Ackland, G A Tannock, I F Young
  Appl Environ Microbiol. 1985 Apr; 49(4):920-924

1984 (4)

• Responses to one or two doses of a deoxycholate subunit influenza vaccine in a primed population.
  G A Tannock, D A Bryce, M J Hensley, N A Saunders, R S Gillett, W S Kennedy
  Vaccine. 1984 Mar; 2(1):100-106
• Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens.
  G A Tannock, J A Paul, R D Barry
  Infect Immun. 1984 Feb; 43(2):457-462
• The sensitization of mice with a wild-type and cold-adapted variant of influenza A virus. II. Secondary cytotoxic T cell responses.
  N K Mak, C Sweet, G L Ada, G A Tannock
  Immunology. 1984 Feb; 51(2):407-416
• A simple procedure for the analysis of the structural proteins of influenza and parainfluenza viruses involving adsorption to erythrocytes.
  J A Cowley, G A Tannock, R D Barry
  J Virol Methods. 1984 Feb; 8(1-2):9-18

1983 (1)

• Immunization against influenza by the ocular route. Brief report.
  G A Tannock, J A Paul, R D Barry
  Arch Virol. 1983 Jan; 78(1-2):133-136

1982 (2)

• Humoral and cellular responses of mice to infection with a cold-adapted influenza A virus variant.
  N K Mak, Y H Zhang, G L Ada, G A Tannock
  Infect Immun. 1982 Oct; 38(1):218-225
• Biophysical and biochemical characterization of hepatitis A virus.
  A G Coulepis, S A Locarnini, E G Westaway, G A Tannock, I D Gust
  Intervirology. 1982 Jan; 18(3):107-127

1981 (4)

• Interferon-new wonder drug or old laboratory curiosity?
  G A Tannock
  Med J Aust. 1981 Oct; 2(7):352-356
• Evidence that the genome of hepatitis A virus consists of single-stranded RNA.
  A G Coulepis, G A Tannock, S A Locarnini, I D Gust
  J Virol. 1981 Jan; 37(1):473-477
• A clearance test in mice using non-adapted viruses to determine the immunogenicity of influenza strains.
  G A Tannock, M C Wark, L E Smith, M M Sutherland
  Arch Virol. 1981 Jan; 70(2):91-101
• The RNA and proteins of human coronaviruses.
  J C Hierholzer, M C Kemp, G A Tannock
  Adv Exp Med Biol. 1981 Jan; 142:43-67

1980 (3)

• A murine model for assessment of living attenuated influenza A vaccines.
  M C Wark, G A Tannock, M M Sutherland, L E Smith
  Aust J Exp Biol Med Sci. 1980 Dec; 58(6):615-626
• Prospects of a living attenuated vaccine against influenza.
  G A Tannock
  Aust J Exp Biol Med Sci. 1980 Oct; 58(5):429-439
• The development of an improved experimental yellow fever vaccine.
  G A Tannock, M C Wark, C G Hair
  J Biol Stand. 1980 Jan; 8(1):23-34

1979 (2)

• The development and evaluation of a cell culture vaccine against infectious laryngotracheitis virus.
  M C Wark, G A Tannock, D Pye
  J Biol Stand. 1979 Jan; 7(1):73-80
• Purification of adenovirus 4 type-specific hemagglutinins for use in diagnostic counterelectrophoresis tests.
  J C Hierholzer, G A Tannock
  J Med Virol. 1979 Jan; 4(4):279-290

1978 (2)

• A comparative evaluation of chicken embryo tracheal organ cultures for the assay of avian infectious bronchitis virus.
  J A Egan, G A Tannock
  J Biol Stand. 1978 Jul; 6(3):205-210
• Presence of genomic polyadenylate and absence of detectable virion transcriptase in human coronavirus OC-43.
  G A Tannock, J C Hierholzer
  J Gen Virol. 1978 Apr; 39(1):29-39

1977 (2)

• Quantitation of antibody to non-hemagglutinating viruses by single radial hemolysis: serological test for human coronaviruses.
  J C Hierholzer, G A Tannock
  J Clin Microbiol. 1977 Jun; 5(6):613-620
• The RNA of human coronavirus OC-43.
  G A Tannock, Hierholzer
  Virology. 1977 May; 78(2):500-510

1975 (2)

• Attempts to extend the genetic map of poliovirus temperature-sensitive mutants.
  P D Cooper, E Geissler, G A Tannock
  J Gen Virol. 1975 Oct; 29(1):109-120
• Degradation of myxovirus virion RNA by periodate.
  G A Tannock, I P Griffith
  Intervirology. 1975 Jan; 5(3-4):150-161

1973 (1)

• The nucleic acid of infectious bronchitis virus.
  G A Tannock
  Arch Gesamte Virusforsch. 1973 Jan; 43(3):259-271

1971 (1)

• Further characterization of the genetic map of poliovirus temperature-sensitive mutants. In: strategy of the viral genome.
  P D Cooper, E Geissler, P D Scotti, G A Tannock
  Ciba Found Symp. 1971 Jan

1970 (1)

• A re-examination of the molecular weight of poliovirus RNA.
  G A Tannock, A J Gibbs, P D Cooper
  Biochem Biophys Res Commun. 1970 Jan; 38(2):298-304

1965 (1)

• Nucleic acid of infectious laryngotracheitis virus.
  G A Tannock
  Nature. 1965 Nov; 208(5011):711-712

News Articles (5)

2016 (1)

• Influenza: New annual vaccines still required

2012 (3)

• What's new in influenza?
• Appeal - just $50,000 from reaching our target
• It's flu season - the merits of vaccination

2011 (1)

• New viral infections course for Burnet